About the event
Wholesale Investor has created a virtual event specifically to highlight Life Sciences, Healthcare, Pharmaceuticals, and Technology, as high-growth sectors.
Streaming live on Tuesday 3rd July, this event will showcase Australasia’s latest, high-growth private, pre-IPO, IPO and listed offerings from a range of sectors.
The Australian Life Science and Healthcare sectors have had some great success stories over the last 12 months. As part of the event, we will be looking to shine a spotlight on this success and provide founders with a platform to present their offering.
* PANEL SESSION *
Investment Trends in Health, Med & Technology
Hsien-Hui Tong, Head, Venture Investing, SGInnovate – As the Head, Venture Investing, Hsien-Hui oversees SGInnovate’s investments efforts, which target high-potential, deep technology startups working on areas such as Artificial Intelligence, Autonomous Vehicles, MedTech and Blockchain.
Damien Slizys, Founder of Kobold Ventures, Dr Slizys has been a registered patent attorney for over twenty years and was formerly an equity partner of a top tier patent attorney firm. He has acted for clients who discovered and commercialised new chemical entities, pharmaceuticals and biological products.
Glenn Cross, Experienced Senior Life Sciences Executive, has spent most of his working life in life sciences progressing from the lab bench to senior executive positions. He over 40 years’ experience in the life sciences sector and have held senior executive roles in both multinational and Australian companies.
Dr. Joseph Mocanu, Managing Partner of Verge HealthTech Fund focusing on early stage healthcare technology companies relevant to emerging markets. Prior to this, Joseph was a scientist researching new cancer therapies, a medical device entrepreneur, and a management consultant for Oliver Wyman where he led life sciences and digital health across Asia.
Leslie Chong, Imugene MD & CEO, has over 20 years of experience in leading clinical and department development in oncology. Most recently, she was the clinical program lead for the approved MEK inhibitor in cell-signalling targeted therapy, cobimetinib/Cotellic.
Other Upcoming Events
Over the last 3 years alone, Wholesale Investor has connected $125million of capital, showcased to over 5000 high net-worth investors and investment groups at events spanning 6 countries and 12 cities.
This year, due to the unforeseen circumstance of COVOID-19, Wholesale Investor has gone completely virtual and remains 100% committed to helping our eco-system continue to thrive through this time. Our online events will provide companies and investors with invaluable networking opportunities on a global scale.
We continue to be recognised by renowned organisations as a leading source for HNW investors and reputable companies as the demand for innovation locally and internationally continues to grow.